{"id":"NCT01814800","sponsor":"ADMA Biologics, Inc.","briefTitle":"Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)","officialTitle":"An Open Label, Multicenter, Study to Evaluate the Pharmacokinetics, Efficacy and Safety of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02","primaryCompletion":"2014-12","completion":"2015-01","firstPosted":"2013-03-20","resultsPosted":"2016-10-05","lastUpdate":"2016-10-05"},"enrollment":59,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immune Deficiency Disorder"],"interventions":[{"type":"BIOLOGICAL","name":"RI-002","otherNames":["Immune Globulin (Human)"]}],"arms":[{"label":"RI-002 Treatment","type":"EXPERIMENTAL"}],"summary":"This is a Phase III, multicenter, open-label study of RI-002 administered as an intravenous infusion of RI-002 (IGIV) every 21 or 28 days in approximately 60 subjects with Primary Immunodeficiency Diseases (PIDD).","primaryOutcome":{"measure":"Number of Serious Bacterial Infections (SBIs) Per Subject Per Year (FDA Guidance for Industry (2008))","timeFrame":"One year","effectByArm":[{"arm":"RI-002 Treatment","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":9,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":59},"commonTop":["Sinusitis","Gastroenteritis viral","Nasopharyngitis","Upper respiratory tract infection","Nausea"]}}